Skip to content

Exploring the brain remodeling mechanism of tDCS treatment for post-stroke cognitive impairment based on fNIRS technology

Exploring the brain remodeling mechanism of tDCS treatment for post-stroke cognitive impairment based on fNIRS technology

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500096638
Enrollment
Unknown
Registered
2025-01-27
Start date
2025-02-01
Completion date
Unknown
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post stroke cognitive impairment

Interventions

Sham group:Pseudoanode tDCS stimulation + cognitive rehabilitation training was given.
Control group:Routine rehabilitation is given.
tDCS group:Anode transcranial direct current stimulation (tDCS) stimulation + cognitive rehabilitation training were given.

Sponsors

Xuzhou Rehabilitation Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. The diagnosis conforms to the diagnostic criteria for Post Stroke Cognitive Impairment (PSCI) as outlined in the 'Expert Consensus on Post Stroke Cognitive Impairment Management 2021' published by the Chinese Stroke Association and the Expert Committee on Post Stroke Cognitive Impairment Management in 2021,MoCA score= 6 points; 2.Age ranges from 40 to 75 years old, all underwent head CT and MRI examinations; 3.Having sufficient visual and auditory resolution to undergo neuropsychological testing and other assessments; 4.First onset within 6 months after stroke,tital signs are stable; 5.The subjects and/or guardians provide informed consent and sign a consent form, which has been approved by the Ethics Committee of Xuzhou Rehabilitation Hospital.

Exclusion criteria

Exclusion criteria: (1) Patients with a history of brain diseases other than cerebrovascular disease, such as brain trauma, progressive supranuclear palsy, epilepsy, chronic subdural hematoma, Huntington's disease, normal pressure hydrocephalus, brain infection, brain tumor or known brain structural abnormalities, etc. (2) Exclude cognitive impairment caused by neurodegenerative diseases, congenital and hereditary diseases such as Alzheimer's disease, Parkinson's disease, Lewy body dementia, etc. (3) Patients with cognitive impairment caused by liver, kidney, thyroid and other systemic diseases, anemia, malnutrition and other reasons are excluded. (4) Patients with impaired consciousness, severe neurological deficits, inability to take care of themselves, severe dementia, etc., who are unable to complete the scale test, were excluded. (5) Exclude a history of alcohol, drug abuse, or dependence within the past 2 years. (6) Exclusion of pseudodementia caused by various other causes. (7) Subjects who, in the opinion of the investigator, are unable to comply with the study procedures. (8) Intracranial metal implants, magnetic sheets, pacemakers, or skull defects; (9) Personal or family history of epilepsy, psychiatric history (including febrile seizures in infancy).

Design outcomes

Primary

MeasureTime frame
Loewenstein Occupational Therapy Cognitive Assessment(LOTCA) Score;

Secondary

MeasureTime frame
Neuroimaging indicators;Neurophysiological indicators;Montreal Cognitive Assessment Scale(MoCA) Score;

Countries

China

Contacts

Public ContactYingli Bi

Xuzhou Rehabilitation Hospital

biyilang@163.com+86 18112000311

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026